miRNA Probe Kit for Accurate Prostate Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing prostate cancer detection methods, particularly the PSA test, suffer from high false positive rates and low sensitivity, leading to overdiagnosis and overtreatment, and existing miRNA markers lack sufficient evidence and reproducibility for reliable prostate cancer detection.
Innovation Solution
A kit and device utilizing nucleic acids that specifically bind to a set of identified miRNAs, including miR-4443, miR-1908-5p, and others, for detecting prostate cancer in blood samples, providing improved sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA test is used for prostate cancer detection, then detection coverage is achieved, but false positive rate increases and sensitivity remains low
Solution Approach 1:
The invention segments the detection process by using multiple independent miRNA markers (miR-4443, miR-1908-5p, miR-4257, etc.) instead of a single PSA marker. Each miRNA is detected separately using specific nucleic acid probes, and their expression levels are combined to improve overall detection accuracy and reduce false positives while enhancing sensitivity.
Solution Approach 2:
The invention creates a composite diagnostic approach by combining multiple miRNA markers into a single detection system. The kit includes nucleic acid probes for detecting several miRNAs simultaneously, and the diagnostic value is determined by the composite expression pattern of these markers, thereby improving reliability and sensitivity beyond what a single marker can achieve.
2Reliability
If existing miRNA markers are used, then detection capability is provided, but sufficient evidence and reproducibility are lacking
Solution Approach 1:
The invention divides the detection system into multiple specific components, each targeting a particular miRNA marker. The kit includes separately optimized nucleic acid probes for each miRNA (miR-4443, miR-1908-5p, miR-4257, etc.), allowing independent validation and detection of each marker's contribution to diagnostic accuracy, thereby improving reproducibility and evidence quality.
Solution Approach 2:
The invention merges multiple miRNA detection capabilities into a single integrated kit and methodology. By combining the detection of several miRNA markers in one system with standardized protocols and controls, the invention enhances both reliability through reproducibility and sensitivity through the synergistic effect of multiple markers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed method significantly enhances the detection of prostate cancer by reducing false positives and improving sensitivity, offering a more accurate diagnostic tool for prostate cancer.
Implementation Method 1
a nucleic acid capable of specifically binding to a particular miRNA
Data Source
AI summary
An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.